Paul Sekhri

Paul Sekhri has over 35 years of experience in the Life Science Industry. His experience encompasses senior management in large corporate pharmaceutical and biotechnology companies, as well as private equity and venture capital. Mr. Sekhri is currently Chairman, President and Chief Executive Officer of vTv Therapeutics, Inc. From 2019 until 2022, he was President and CEO of eGenesis, Inc. From 2015 until 2018 Mr. Sekhri served as President and CEO of Lycera Corp. Prior to this, he served as Senior Vice President, Integrated Care for Sanofi from April 2014 through January 2015. Previously, he served as Group Executive Vice President, Global Business Development and Chief Strategy Officer for Teva Pharmaceutical Industries, Ltd. Prior to joining Teva, he spent five years as Operating Partner and Head of the Biotechnology Operating Group at TPG Biotech, the life sciences venture capital arm of TPG Capital.
From 2004 - 2009, Mr. Sekhri was Founder, President, and Chief Executive Officer of Cerimon Pharmaceuticals, Inc. Prior to founding Cerimon, Mr. Sekhri was President and Chief Business Officer of ARIAD Pharmaceuticals, Inc. Previously, Mr. Sekhri spent five years at Novartis as Senior Vice President, and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG.
Mr. Sekhri has been a director on more than 40 private, public company, and non-profit Boards, and is currently a member of the Board of Directors of AdhereTech, Likeminds, Spring Discovery, and Veeva Systems Inc. Mr. Sekhri is also the Chairman of the Boards of Directors of Compugen Ltd., Resolution Therapeutics, and Kaerus Bioscience. He was also Chairman of Longboard Pharmaceuticals until it’s sale to Lundbeck A/S in December 2024. Additionally, he was on the Board of Directors of Carnegie Hall, The Metropolitan Opera, and is on the Advisory Council of the New York Philharmonic and Chairman of Young Concert Artists, Inc.